Pacira BioSciences, Inc. (PCRX) Financial Statements (2023 and Earlier)

Company Profile

Business Address 5401 WEST KENNEDY BOULEVARD
TAMPA, FL 33609
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments656522292383311173159
Cash and cash equivalents58610078133543657
Short-term investments71422214251257137102
Receivables96534838323026
Inventory, net of allowances, customer advances and progress billings99655849413162
Inventory99655849413162
Other undisclosed current assets1512118796
Total current assets:866652409478391243253
Noncurrent Assets
Operating lease, right-of-use asset7674 
Property, plant and equipment18813710510910710190
Long-term investments and receivables 95652660 13
Long-term investments 95652660 13
Intangible assets, net (including goodwill)76919620462554731
Goodwill14510010062554731
Intangible assets, net (excluding goodwill)62497104   0
Deferred income tax assets153106 
Other noncurrent assets   1112
Other undisclosed noncurrent assets2214491414  
Total noncurrent assets:1,209623423211237148137
TOTAL ASSETS:2,0751,275831689628391390
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities139828560564444
Accounts payable111013141589
Accrued liabilities128717046413735
Taxes payable0010000
Debt375150 00  
Asset retirement obligation  1    
Deferred revenue and credits011
Other undisclosed current liabilities82223   106
Total current liabilities:521253108615645152
Noncurrent Liabilities
Long-term debt and lease obligation746384306291276109 
Long-term debt, excluding current maturities675313306291276109 
Operating lease, liability7271 
Liabilities, other than long-term debt214217161920
Deferred revenue and credits 78
Deferred revenue10  
Deferred compensation liability, classified1      
Other liabilities104217161111
Other undisclosed noncurrent liabilities561461    
Total noncurrent liabilities:82440136830729312820
Total liabilities:1,345655476368349172171
Stockholders' equity
Stockholders' equity attributable to parent730620355321279219218
Common stock0000000
Additional paid in capital942873754710669565527
Accumulated other comprehensive income (loss)000(0)(0)(0)(0)
Accumulated deficit(212)(254)(399)(388)(389)(346)(308)
Total stockholders' equity:730620355321279219218
TOTAL LIABILITIES AND EQUITY:2,0751,275831689628391390

Income Statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues542430421337287276249
Revenue, net334286273248
Cost of revenue(140)(117)(107)(87)(88)(110)(72)
Gross profit:401312314250199166177
Operating expenses(268)(261)(411)(321)(312)(308)(240)
Other undisclosed operating income (loss)(43)(5)107878811072
Operating income (loss):90461016(25)(32)9
Nonoperating expense(34)(26)(21)(16)(18)(6)(7)
Investment income, nonoperating1576411
Other nonoperating income (expense)(3)3(5)(1)0(0)(0)
Interest and debt expense(32)(8)(24)(22)(4)(7)(0)
Income (loss) from continuing operations before equity method investments, income taxes:2512(34)(22)(46)(45)2
Other undisclosed income from continuing operations before income taxes3282422470
Income (loss) from continuing operations before income taxes:5620(11)(0)(42)(38)2
Income tax expense (benefit)(14)125(0)(0)(0)(0)(0)
Net income (loss) available to common stockholders, diluted:42146(11)(0)(43)(38)2

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):42146(11)(0)(43)(38)2
Comprehensive income (loss):42146(11)(0)(43)(38)2
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)10(0)00
Comprehensive income (loss), net of tax, attributable to parent:42146(10)(0)(43)(38)2

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: